Burning rock reports first quarter 2024 financial results

Guangzhou, china, may 29, 2024 (globe newswire) -- burning rock biotech limited (nasdaq: bnr and lse: bnr, the “company” or “burning rock”), a company focused on the application of next generation sequencing (ngs) technology in the field of precision oncology, today reported financial results for the three months ended march 31, 2024. recent business updates early detection thunder study for 6-cancer test was included in the diagnosis and treatment guidelines for primary liver cancer (2024 edition) and the expert consensus on detection and clinical application of tumor dna methylation markers (2024 edition), showing an impressive performance of elsa-seq using cfdna in cancer detection and origin prediction.
BNR Ratings Summary
BNR Quant Ranking